Cysteamine Blocks Amphetamine-Induced Deficits in Sensorimotor Gating

Somatostatin is a neuropeptide that has been shown to interact with dopamine. Low concentrations of cysteamine selectively depletes somatostatin and has been used to investigate the role of endogenous somatostatin in lieu of an available selective receptor antagonist. We examined the effects of vari...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology, biochemistry and behavior biochemistry and behavior, 1997-11, Vol.58 (3), p.689-693
Main Authors: Feifel, David, Minor, Kelly L
Format: Article
Language:English
Subjects:
Acoustic Stimulation
Amphetamine - antagonists & inhibitors
Amphetamine - pharmacology
Animals
Biological and medical sciences
Cysteamine
Cysteamine - pharmacology
Dopamine
Dopamine Uptake Inhibitors - antagonists & inhibitors
Dopamine Uptake Inhibitors - pharmacology
Drug toxicity and drugs side effects treatment
Male
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Prepulse inhibition
Rats
Rats, Sprague-Dawley
Reflex, Startle - drug effects
Schizophrenia
Sensorimotor gating
Somatostatin
Somatostatin - physiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Somatostatin is a neuropeptide that has been shown to interact with dopamine. Low concentrations of cysteamine selectively depletes somatostatin and has been used to investigate the role of endogenous somatostatin in lieu of an available selective receptor antagonist. We examined the effects of various doses of subcutaneous cysteamine on baseline and amphetamine-disrupted sensorimotor gating as measured by prepulse inhibition of the acoustic startle reflex. Cysteamine in doses ranging from 50–300 mg/kg reversed decreases in PPI induced by systemic injections of amphetamine (2 mg/kg). Cysteamine had no effect on the amplitude of the acoustic startle reflex itself. The results lend further support to a somatostatin–dopamine interaction within the brain in which endogenous somatostatin facilitates dopaminergic activity. These findings also suggest that endogenous somatostatin might play a significant role in regulation of sensorimotor gating deficits. This has clinical implications as deficient prepulse inhibition is recorded in humans suffering from neuropsychiatric conditions such as schizophrenia.
ISSN:0091-3057
1873-5177
DOI:10.1016/S0091-3057(97)00020-8